טוען...
Identification of a New Potent Inhibitor Targeting KRAS in Non-small Cell Lung Cancer Cells
KRAS (v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog) is an oncogenic driver with mutations in 30% of non-small cell lung cancer (NSCLC). However, there is no effective clinical drug even though it has been identified as an oncogene for 30 years. In this study, we identified a small molecule i...
שמור ב:
| הוצא לאור ב: | Front Pharmacol |
|---|---|
| Main Authors: | , , , , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Frontiers Media S.A.
2017
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5694459/ https://ncbi.nlm.nih.gov/pubmed/29184501 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fphar.2017.00823 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|